BYD
27.2.2024 16:21:34 CET | Business Wire | Press release
At the Geneva Motor Show on February 26, the World Car Awards announced the top three finalists for 2024. BYD's models, the BYD SEAL and the BYD DOLPHIN, excelled among a host of competitors, securing spots in the top three for the "World Car of the Year" and "World Urban Car" categories, respectively, and progressing to the final round of the competition. BYD makes history as the first and only Chinese carmaker to be shortlisted in the top three for the "World Car of the Year" category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240227393340/en/
BYD SEAL shortlisted in the Top 3 for the "World Car of the Year" category (Photo: Business Wire)
Regarded as the top three automotive accolades globally, the "World Car Awards," "European Car of the Year," and "North American Car of the Year" are highly esteemed. Dubbed the "Oscars of the automotive world", the "World Car Awards" is particularly celebrated for its emphasis on international models, positioning it as a highly anticipated event within the global automotive industry. BYD's exceptional performance highlights its status as a global leader in the New Energy Vehicle space.
These two models, with their distinctive design, cutting-edge technology, and robust safety features, captured the interest of over 100 automotive media experts from 29 countries. In 2023, the BYD SEAL and BYD DOLPHIN achieved five-star ratings in Euro NCAP and ANCAP tests. Notably, BYD SEAL was also nominated for the final European Car of the Year 2024.
As a frontrunner in the new energy vehicle sector, BYD achieved a milestone with over 3 million new energy vehicle sales in 2023, securing the top spot in global sales, for the second year in a row and breaking into the top ten global automotive brands — a first for a Chinese automaker.
So far, BYD's new energy vehicles have a substantial presence across over 70 countries and regions on six continents, encompassing more than 400 cities. In 2023, BYD emerged as a frontrunner in new energy vehicle sales across various international markets, including Thailand, Singapore, Colombia, and Brazil, garnering extensive consumer acclaim and preference.
Aligning with the World Car Awards' mission to foster continual innovation in the automotive sector, BYD is committed to building a comprehensive zero-emission new energy solution through technological innovations. It aims to enhance consumer travel experiences, spearhead the new energy vehicle industry's growth, and actively contribute to the automotive industry's transformation and progress. Looking ahead, BYD will steadfastly pursue its vision to "Cool the Earth by 1°C," continually driving the industry's green and low-carbon transformation and global sustainable development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227393340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom